Diagnosis, Staging and Treatment of Patients with Lung Cancer

Objectives

This national clinical guideline provides an evidence-based framework for the diagnosis, staging and treatment of adults aged 18 years or over with newly diagnosed or suspected lung cancer in hospital settings. It aims to improve the quality, safety, consistency and cost-effectiveness of care, reduce unwarranted clinical variation, improve outcomes and quality of life, reduce morbidity and mortality where possible, promote beneficial interventions and discourage ineffective practice.[1][2][3][4][5]

• Standardise multidisciplinary lung cancer care across radiology, respiratory medicine, pathology, surgery, medical oncology, radiation oncology and palliative care.[6][7]
• Prioritise clinical questions where practice is uncertain or variable, new evidence has emerged, or guidance can have the greatest effect on care.[5]
• Strengthen accurate diagnosis, pathological classification and staging through appropriate imaging, tissue sampling, mediastinal assessment and molecular analysis.[8][9][10][11]
• Support stage-appropriate treatment, including surgery, radiotherapy, systemic anticancer therapy, multimodality treatment, symptom management and specialist palliative care.[12][13][14][15]
• Promote curative-intent treatment where clinically appropriate, while tailoring decisions to tumour characteristics, physiological fitness, co-morbidity, performance status, patient preference and multidisciplinary assessment.[9][16][17][18]
• Provide survivorship support and patient information intended to support quality of life and prolonged survival for patients and their significant others.[5]
• Prioritise research on local ablative therapies for high-risk surgical candidates, imaging surveillance after curative treatment and the role of magnetic resonance imaging in staging.[19]

Implementation

Implementation relies on multidisciplinary delivery in acute hospitals, supported by the National Cancer Control Programme (NCCP), cancer centres, Hospital Groups and clinical leadership. Corporate responsibility rests with hospital chief executive officers, general managers and clinical directors, while each multidisciplinary team member is responsible for applying recommendations within their professional discipline.[1][20][5]Guideline development and revision use systematic evidence review, clinical expertise, stakeholder consultation, external review and conflict-of-interest management, with recommendations assessed for evidence quality, applicability, patient benefit and harm, health-system impact and resource implications.[21][22][23]

• Deliver care through multidisciplinary teams that coordinate diagnostic testing, surgery, radiotherapy, chemotherapy and palliative care, and discuss complex treatment decisions and staging at team meetings.[7][24][25]
• Govern development through a multidisciplinary Guideline Steering Group chaired by the NCCP Director and a Guideline Development Group comprising clinical specialists, a project manager, methodologist, research officer and clinical librarian.[21]
• Apply evidence-based practice by formulating clinical questions, conducting systematic searches, appraising literature and economic evidence, developing graded recommendations, consulting stakeholders and undertaking external review.[26][21][22]
• Disseminate the guideline through professional networks and the National Clinical Effectiveness Committee and NCCP websites, supported by multidisciplinary implementation tools and initiatives for referral, electronic referral, patient information and survivorship care.[5][19]
• Use the COM-B behaviour-change model to identify capability, opportunity and motivation barriers and select implementation functions such as education, training, enablement, persuasion and environmental restructuring.[23][27]
• Review implementation through regular NCCP discussions with cancer centres, Hospital Groups and senior management covering performance data, improvement plans, staffing, resources and service development.[28][19]
• Monitor quality through key performance indicators developed by the Lung National Clinical Leads Network, annual multidisciplinary Cancer Quality and Audit Fora, national audits of clinical processes and patient outcomes, and quarterly cancer-centre performance meetings.[5][23][19][25]
• Apply specified service measures, including recording clinical tumour, node and metastasis stage at multidisciplinary meetings for at least 95% of patients with primary lung cancer, offering first surgery within 30 working days of the decision to operate, and starting intravenous systemic treatment within 15 working days of a finalised treatment plan.[25]
• Maintain the guideline as a live document through literature surveillance and review at three-year intervals, with updates subject to National Clinical Effectiveness Committee approval.[21][23]
• Seek any additional implementation resources through the Health Service Executive service-planning process; most recommendations are considered cost neutral because they reflect existing standard practice, while practice changes are subject to budget impact assessment.[7][29]
• Commission and fund the guideline through the NCCP while maintaining independence of its recommendations from funding bodies.[21]

Monitoring & Evaluation

The guideline establishes a national monitoring and accountability architecture combining implementation oversight, clinical audit, performance review, evidence surveillance and scheduled updating.[5][21][23][19]

• Develop and agree key performance indicators through the Lung National Clinical Leads Network, although the supplied material does not list the individual indicators.[5]
• Organise annual multidisciplinary Cancer Quality and Audit Fora and use regular National Cancer Control Programme meetings with cancer centres, Hospital Groups and senior management to review performance data, improvement plans, staffing, resources, service planning and development.[5][19]
• Hold quarterly meetings between the National Cancer Control Programme Cancer Network Manager and each cancer centre for performance monitoring and service planning.[23]
• Audit both guideline implementation and patient outcomes using the audit criteria and monitoring arrangements in Appendix 8.[19]
• Maintain the guideline as a live document through periodic literature surveillance and review it three years after its 2017 publication; subject interim and three-year updates to National Clinical Effectiveness Committee approval and record them on relevant websites.[21][23]

Implementation accountability is shared between hospital corporate leadership and multidisciplinary teams: the Chief Executive Officer, General Manager and Clinical Director hold corporate responsibility, while each team member is responsible for recommendations relevant to their discipline.[5][23]Relevant medical staff are expected to comply with the guideline and associated procedures, work within professional standards and maintain competence in lung-cancer management.[23]

Clinical monitoring includes explicit process standards for diagnosis and treatment. Record clinical tumour, node and metastasis staging at the multidisciplinary meeting for at least 95% of patients diagnosed with primary lung cancer; record pathological staging, resection volume and type, and intraoperative mediastinal nodal staging for resected cases.[25]Resection pathology reports should contain Royal College of Pathologists minimum-dataset prognostic indicators and be reported by a designated pathologist.[25]

• Provide surgery within 30 working days of the multidisciplinary team decision when surgery is the first treatment.[25]
• Administer the first intravenous systemic-treatment cycle within 15 working days of the day ward receiving the finalised treatment plan.[25]
• Initiate treatment for small-cell lung cancer within 10 working days of histological diagnosis and deliver radiotherapy promptly.[25]
• Monitor radiotherapy safety through dose-volume parameters, including lung dose-volume histograms, mean lung dose and doses to the oesophagus, spinal cord and heart.[30][31]
• Use clinical assessment and periodic computed tomography for follow-up after curative-intent surgery or radiotherapy, while recognising that the optimal imaging interval is not established.[32]

The document also provides evidence-based clinical performance measures, such as diagnostic sensitivity, specificity, treatment response, survival, toxicity, quality of life and recurrence, but these are primarily evidence-review outcomes rather than a complete routine reporting framework.[33][34][35][36]The supplied material does not specify detailed reporting templates, national surveillance registries, outcome targets beyond the stated process standards, or a comprehensive timetable for public reporting.[5][21][23][25]

Costing & Financing

Financing is centred on National Cancer Control Programme commissioning, Health Service Executive service planning, budget-impact assessment and medicine reimbursement processes; no overall implementation budget or quantified funding gap is specified.[21][7][29][37]

• Fund the guideline through the National Cancer Control Programme while maintaining content independence from funders.[21]
• Assess recommendations with resource implications through a budget impact assessment and seek additional resources through the Health Service Executive service-planning process.[7][29]
• Appraise economic evidence using the Scottish Intercollegiate Guidelines Network economic filter and validated economic checklists, with health-economist input.[22][21]
• Manage new cancer-medicine reimbursement through the Health Service Executive, National Centre for Pharmacoeconomics health technology assessments and National Cancer Control Programme Technology Review Committee recommendations to the Health Service Executive Drugs Group.[37]
• Include financial provision for new medicines in the annual Health Service Executive Service Plan, approved by the Department of Health.[37]

Most recommendations are considered cost neutral because they reflect current standard practice, although changes in practice may require additional resources.[7]Identified implementation pressures include access to positron emission tomography-computed tomography and software for multidisciplinary review, thoracoscopy, radiotherapy technology and planning capacity, rapid on-site diagnostic evaluation, expanded specialist palliative care, surgical and pathology capacity, and staff training.[38][39][40][41][25]

The guideline identifies an implementation-audit cost of €162,000, calculated as €27,000 twice yearly for three years.[27]It also quantifies €131 per restaging computed tomography scan for 483 procedures, totalling €63,273.[42]Several recommendation-table entries are recorded as €0, but the source does not explain whether this denotes no additional cost, a cost-neutral assumption or unavailable costing.[10][11]

Economic evidence suggests that diagnostic and treatment choices may be cost-effective in selected settings but remains sensitive to study design, comparator choice, clinical assumptions and applicability to Ireland.[43][44][45]Navigational bronchoscopy relative to positron emission tomography had an adjusted incremental cost-effectiveness ratio of €3,945 per quality-adjusted life year, below the €45,000 threshold applied in Ireland.[43]Stereotactic body radiotherapy relative to radiofrequency ablation had an adjusted incremental cost-effectiveness ratio of €12,500 per quality-adjusted life year.[46]

At the wider economic level, lung cancer had the highest estimated overall cancer cost in the European Union in 2009, at €18.8 billion, including inpatient care, productivity losses from mortality and informal-care costs.[7]These estimates describe economic burden rather than a dedicated Irish guideline budget or financing commitment.[7]